MetaCap

electroCore (ECOR) vs Stereotaxis (STXS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

electroCore (ECOR) has outperformed Stereotaxis (STXS) over the past year, losing 6.2% versus a loss of 59.4%. Over five years, ECOR leads with a -61.2% price change compared with -84.2% for STXS. Stereotaxis is the larger company by market cap ($95.0 million vs $40.8 million), about 2.3 times the size, while electroCore is growing revenue faster (+27.2% vs +20.3%).

electroCore converts more of its revenue into profit, with a net margin of -43.6% versus -66.8%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ECOR-6.16%STXS-59.39%
+172%+48%-77%
Nov 21, 20251 yearNov 20, 2026
ECOR-61.13%STXS-85.37%
+63%-16%-94%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ECOR versus STXS key metrics
MetricECORSTXS
Share price$4.42$0.9422
Market cap$40.78M$95.03M
1-day change-8.87%-6.71%
YTD return-1.45%-59.03%
1-year return-6.16%-59.39%
5-year return-61.23%-84.16%
EPS (TTM)$-1.36$-0.24
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$32.03M$32.38M
Revenue growth (YoY)+27.20%+20.28%
Net income (latest FY)$-13.97M$-21.64M
Gross margin86.75%52.73%
Operating margin-41.06%-68.30%
Net margin-43.60%-66.85%
52-week high$12.70$2.86
52-week low$3.90$0.80
Distance from 52-week high-65.20%-67.06%
Analyst consensusnonenone
Avg. price target upside+333.71%+218.40%
Average volume120.32K715.12K
Shares outstanding9.23M100.86M
Employees83131
SectorHealth CareHealth Care
IndustryBiotechnology: Electromedical & Electrotherapeutic ApparatusBiotechnology: Electromedical & Electrotherapeutic Apparatus

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Stereotaxis is about 2.3 times larger than electroCore by market value ($95.03M vs $40.78M).
  • ECOR has outperformed STXS by 53.2 percentage points over the past year.
  • electroCore is more profitable, keeping -43.6 cents of every revenue dollar as net income versus -66.8 cents for Stereotaxis.
  • electroCore grew revenue faster in its latest fiscal year (+27.20% vs +20.28%).

About electroCore

ECOR stock →

electroCore, Inc., a bioelectronic technology medicine and general wellness company, provides non-invasive vagus nerve stimulation (nVNS) technology platform in the United States, the United Kingdom, and internationally. The company develops gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania.

Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 83 employees

About Stereotaxis

STXS stock →

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally.

Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 131 employees

ECOR vs STXS FAQ

Which is bigger, electroCore or Stereotaxis?

Stereotaxis (STXS) is larger, with a market capitalization of $95.03M compared with $40.78M for electroCore (ECOR).

Which stock has performed better over the past year, ECOR or STXS?

ECOR returned -6.16% over the past 12 months, compared with -59.39% for STXS (price return, excluding dividends). Past performance does not predict future results.

Are electroCore and Stereotaxis in the same industry?

Yes. Both are classified in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry within the Health Care sector.

More comparisons